Skip to Main content Skip to Navigation
Journal articles

Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-α antagonists.

Abstract : Patients under immunosuppressive therapy with tumor necrosis factor alpha (TNF-α) antagonists are vulnerable to various opportunistic infections including leishmaniasis. We present a case series of 8 travellers developing cutaneous leishmaniasis whilst on TNF-α antagonist treatment and review the literature on aspects of cutaneous leishmaniasis developing in patients treated with TNF-α antagonists. We make interim recommendations regarding the drug therapy used to maintain remission in travellers with rheumatoid disease travelling to leishmania prone areas. Despite having a medical condition requiring continued rheumatological review the interval to diagnosis appears not to be reduced compared to that described in non-rheumatoid patients. Rheumatologists and family doctors should be aware of the need for post-travel surveillance for leishmaniasis in rheumatoid patients on TNF-alpha antagonist treatment.
Document type :
Journal articles
Complete list of metadatas

https://hal-pasteur.archives-ouvertes.fr/pasteur-00939151
Contributor : Gloria Morizot <>
Submitted on : Thursday, January 30, 2014 - 11:28:09 AM
Last modification on : Wednesday, August 19, 2020 - 11:16:45 AM

Identifiers

Collections

Citation

Andreas L C Neumayr, Gloria Morizot, Leo G Visser, Diana N J Lockwood, Bernhard R Beck, et al.. Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-α antagonists.. Travel Medicine and Infectious Disease, Elsevier, 2013, 11 (6), pp.412-20. ⟨10.1016/j.tmaid.2013.05.003⟩. ⟨pasteur-00939151⟩

Share

Metrics

Record views

258